PTC Therapeutics, Inc. (PTCT) Revenue, Earnings & Financial Statements
$60.36NMS: PTCTMarket Cap $5.04B
Data as of Nov 17, 2026 close · Statements through the quarter ended Sep 2026 · Source: Financial Modeling Prep (methodology)
PTC Therapeutics, Inc. most recently reported annual revenue of $1.7B, net profit of $683.0M. Revenue grew at an average annual rate of 35.4% over the last 5 fiscal years. See the full income statement, balance sheet, and cash flow statement below, plus valuation and return ratios.
PTC Therapeutics, Inc.: Revenue rose from $83.0M in 2016 to $1.7B in 2025, a change of +1985.5% over 9 years; net profit was positive in 1 of 10 reported years; operating margin moved from -159.7% to 49.5%, a shift of +209.2 percentage points; the most recent year shows net profit of $683.0M.
Income Statement — 10 Years (USD millions)
Metric
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Revenue
$83.0M
$194.0M
$265.0M
$307.0M
$381.0M
$539.0M
$699.0M
$938.0M
$807.0M
$1.7B
Operating Expenses
$215.0M
$259.0M
$380.0M
$548.0M
$813.0M
$913.0M
$1.1B
$1.4B
$1.1B
$874.0M
Operating Profit
−$132.0M
−$64.0M
−$116.0M
−$241.0M
−$432.0M
−$374.0M
−$447.0M
−$440.0M
−$303.0M
$857.0M
Operating Margin
-159.7%
-33.1%
-43.7%
-78.6%
-113.4%
-69.5%
-64.0%
-46.9%
-37.5%
49.5%
Other Income
−$9.0M
−$13.0M
−$12.0M
$1.0M
$29.0M
−$144.0M
−$140.0M
−$257.0M
−$61.0M
−$160.0M
Interest
$8.0M
$12.0M
$13.0M
$12.0M
$56.0M
$86.0M
$91.0M
$129.0M
$167.0M
$152.0M
Depreciation
$3.0M
$18.0M
$26.0M
$32.0M
$43.0M
$64.0M
$129.0M
$237.0M
$76.0M
$39.0M
Profit Before Tax
−$142.0M
−$78.0M
−$128.0M
−$240.0M
−$403.0M
−$518.0M
−$587.0M
−$696.0M
−$363.0M
$697.0M
Tax rate (%)
-0.4%
-1.7%
0.0%
-4.9%
-8.7%
-1.1%
4.8%
10.0%
-0.1%
2.0%
Net Profit
−$142.0M
−$79.0M
−$128.0M
−$252.0M
−$438.0M
−$524.0M
−$559.0M
−$627.0M
−$363.0M
$683.0M
EPS
−$4.17
−$2.02
−$2.75
−$4.27
−$6.64
−$7.43
−$7.79
−$8.37
−$4.73
$7.78
Quarterly Results — Last 12 Quarters (USD millions)
8 duplicate period labels in the source data were collapsed.
Metric
Dec '23
Mar '24
Jun '24
Sep '24
Dec '24
Mar '25
Jun '25
Sep '25
Dec '25
Mar '26
Jun '26
Sep '26
Revenue
$307.0M
$210.0M
$187.0M
$197.0M
$213.0M
$1.2B
$179.0M
$211.0M
$165.0M
$273.0M
$361.0M
$358.0M
Operating Expenses
$304.0M
$256.0M
$227.0M
$251.0M
$376.0M
$206.0M
$214.0M
$208.0M
$246.0M
$227.0M
$212.0M
$333.0M
Operating Profit
$3.0M
−$45.0M
−$40.0M
−$55.0M
−$162.0M
$970.0M
−$35.0M
$3.0M
−$82.0M
$46.0M
$149.0M
$25.0M
Operating Margin
1.0%
-21.6%
-21.5%
-27.7%
-76.2%
82.5%
-19.5%
1.4%
-49.6%
16.8%
41.3%
7.0%
Interest
$44.0M
$41.0M
$43.0M
$42.0M
$41.0M
$34.0M
$30.0M
$33.0M
$55.0M
$49.0M
$48.0M
$46.0M
Profit Before Tax
−$157.0M
−$85.0M
−$86.0M
−$98.0M
−$95.0M
$930.0M
−$71.0M
−$23.0M
−$139.0M
−$2.0M
$98.0M
−$41.0M
Tax rate (%)
0.8%
-8.1%
-15.7%
-8.8%
30.4%
6.8%
8.7%
168.9%
3.0%
-14.1%
14.4%
-25.8%
Net Profit
−$156.0M
−$92.0M
−$99.0M
−$107.0M
−$66.0M
$867.0M
−$65.0M
$16.0M
−$135.0M
−$3.0M
$83.0M
−$52.0M
EPS
−$2.06
−$1.20
−$1.29
−$1.39
−$0.85
$10.04
−$0.83
$0.20
−$1.67
−$0.03
$0.92
−$0.62
Over the 10 years reported for PTC Therapeutics, Inc., borrowings increased from $98.0M in 2016 to $2.7B in 2025, cash stood at $985.0M in the latest year, shareholders' equity was $0, current assets covered current liabilities 2.35 times.
Balance Sheet — 10 Years (USD millions)
Metric
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Total Assets
$269.0M
$392.0M
$1.1B
$1.6B
$2.2B
$1.9B
$1.7B
$1.9B
$1.7B
$2.9B
Current Assets
$261.0M
$249.0M
$321.0M
$779.0M
$1.2B
$954.0M
$694.0M
$1.2B
$1.4B
$2.3B
Cash
$232.0M
$191.0M
$228.0M
$288.0M
$209.0M
$190.0M
$280.0M
$594.0M
$780.0M
$985.0M
Inventory
$0
$11.0M
$16.0M
$19.0M
$19.0M
$16.0M
$22.0M
$31.0M
$23.0M
$80.0M
Receivables
$25.0M
$40.0M
$68.0M
$56.0M
$70.0M
$110.0M
$156.0M
$161.0M
$159.0M
$182.0M
Fixed Assets
$7.0M
$8.0M
$13.0M
$35.0M
$118.0M
$130.0M
$175.0M
$179.0M
$118.0M
$135.0M
Capital Work in Progress
$0
$0
$0
$0
$0
$0
$0
$0
$0
$0
Investments
$0
$0
$0
$399.0M
$895.0M
$584.0M
$131.0M
$283.0M
$360.0M
$961.0M
Other Assets
$0
$0
$82.0M
$82.0M
$82.0M
$82.0M
$82.0M
$82.0M
$82.0M
$82.0M
Total Liabilities
$150.0M
$235.0M
$768.0M
$1.0B
$1.7B
$1.9B
$2.1B
$2.7B
$2.8B
$3.1B
Current Liabilities
$50.0M
$82.0M
$167.0M
$236.0M
$277.0M
$509.0M
$406.0M
$603.0M
$581.0M
$968.0M
Borrowings
$98.0M
$145.0M
$153.0M
$328.0M
$420.0M
$1.3B
$1.5B
$2.2B
$2.5B
$2.7B
Other Liabilities
$52.0M
$90.0M
$615.0M
$701.0M
$1.3B
$667.0M
$591.0M
$485.0M
$332.0M
$397.0M
Equity
$0
$0
$0
$0
$0
$0
$0
$0
$0
$0
Reserves
$120.0M
$156.0M
$351.0M
$594.0M
$482.0M
$1.0M
−$347.0M
−$819.0M
−$1.1B
−$205.0M
For PTC Therapeutics, Inc., operating cash flow was positive in 1 of 10 reported years; free cash flow in the latest year was $411.0M; free cash flow was positive in 1 of 10 years.
Cash Flow Statement — 10 Years (USD millions)
Metric
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Operating Cash Flow
−$104.0M
−$10.0M
−$28.0M
−$99.0M
−$194.0M
−$251.0M
−$357.0M
−$158.0M
−$108.0M
$711.0M
Investing Cash Flow
$209.0M
$26.0M
−$45.0M
−$433.0M
−$618.0M
$134.0M
$138.0M
−$297.0M
−$30.0M
−$1.2B
Financing Cash Flow
$1.0M
$4.0M
$14.0M
$22.0M
$687.0M
$0
−$31.0M
$948.0M
$257.0M
$234.0M
Net Cash Flow
$0
$53.0M
$58.0M
$126.0M
−$79.0M
−$19.0M
$99.0M
$314.0M
$185.0M
$203.0M
Free Cash Flow
−$105.0M
−$13.0M
−$43.0M
−$144.0M
−$250.0M
−$337.0M
−$509.0M
−$279.0M
−$182.0M
$411.0M
Valuation & Return Ratios
Metric
Value
PEG Ratio
0.64
EV / EBITDA
29.10
FCF Yield
-0.77%
Quick Ratio
3.13
Interest Coverage
0.70
Return 1Y
-15.29%
Return 3Y
212.30%
Return 5Y
64.33%
PTC Therapeutics, Inc. (PTCT) financials — frequently asked questions
What is PTC Therapeutics, Inc.'s annual revenue?
PTC Therapeutics, Inc. (PTCT) reported annual revenue of $1.7B in its most recent fiscal year.
What is PTC Therapeutics, Inc.'s net profit?
PTC Therapeutics, Inc. (PTCT) reported net profit of $683.0M in its most recent fiscal year.
What is PTCT EV/EBITDA?
PTC Therapeutics, Inc.'s enterprise value to EBITDA (EV/EBITDA) ratio is 29.10.
Revenue and earnings of other Biotechnology stocks